These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 22265994

  • 1. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.
    Laval G, Rousselot H, Toussaint-Martel S, Mayer F, Terrebonne E, François E, Brixi H, Nguyen T, Bourdeix I, Bisot-Locard S, Zelek L, SALTO Study Group.
    Bull Cancer; 2012 Feb 01; 99(2):E1-9. PubMed ID: 22265994
    [Abstract] [Full Text] [Related]

  • 2. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
    Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I.
    Jpn J Clin Oncol; 2010 Aug 01; 40(8):739-45. PubMed ID: 20410056
    [Abstract] [Full Text] [Related]

  • 3. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K, Tsilika E, Kalaidopoulou O, Chondros K, Georgaki S, Papadimitriou L.
    Anticancer Res; 2002 Aug 01; 22(2B):1187-92. PubMed ID: 12168923
    [Abstract] [Full Text] [Related]

  • 4. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S, Porzio G.
    Crit Rev Oncol Hematol; 2012 Sep 01; 83(3):388-92. PubMed ID: 22277783
    [Abstract] [Full Text] [Related]

  • 5. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G, Franchi M, Mariani A, Zanaboni F, Rabaiotti E, Frigerio L, Bolis PF, Ferrari A.
    Gynecol Oncol; 1996 Jun 01; 61(3):345-8. PubMed ID: 8641613
    [Abstract] [Full Text] [Related]

  • 6. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
    Massacesi C, Galeazzi G.
    Palliat Med; 2006 Oct 01; 20(7):715-6. PubMed ID: 17060271
    [Abstract] [Full Text] [Related]

  • 7. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.
    J Pain Symptom Manage; 2005 Dec 01; 30(6):563-9. PubMed ID: 16376743
    [Abstract] [Full Text] [Related]

  • 8. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X, Wang P, Li S, Zhang G, Hu S.
    World J Surg Oncol; 2015 Feb 15; 13():50. PubMed ID: 25889313
    [Abstract] [Full Text] [Related]

  • 9. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
    Watari H, Hosaka M, Wakui Y, Nomura E, Hareyama H, Tanuma F, Hattori R, Azuma M, Kato H, Takeda N, Ariga S, Sakuragi N.
    Int J Gynecol Cancer; 2012 May 15; 22(4):692-6. PubMed ID: 22343971
    [Abstract] [Full Text] [Related]

  • 10. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.
    Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O, Mayeur D, Herve R, Maisonobe P, Chauvenet L.
    J Clin Oncol; 2012 Dec 10; 30(35):4337-43. PubMed ID: 23109694
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
    Shima Y, Ohtsu A, Shirao K, Sasaki Y.
    Jpn J Clin Oncol; 2008 May 10; 38(5):354-9. PubMed ID: 18490369
    [Abstract] [Full Text] [Related]

  • 12. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
    Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K.
    J Pain Symptom Manage; 2015 May 10; 49(5):814-21. PubMed ID: 25462210
    [Abstract] [Full Text] [Related]

  • 13. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y, Yamaguchi K, Miyata Y, Hyodo I, Yagi Y, Honke Y.
    Gan To Kagaku Ryoho; 2004 Sep 10; 31(9):1377-82. PubMed ID: 15446560
    [Abstract] [Full Text] [Related]

  • 14. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
    Caroli A, Perico N, Perna A, Antiga L, Brambilla P, Pisani A, Visciano B, Imbriaco M, Messa P, Cerutti R, Dugo M, Cancian L, Buongiorno E, De Pascalis A, Gaspari F, Carrara F, Rubis N, Prandini S, Remuzzi A, Remuzzi G, Ruggenenti P, ALADIN study group.
    Lancet; 2013 Nov 02; 382(9903):1485-95. PubMed ID: 23972263
    [Abstract] [Full Text] [Related]

  • 15. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
    Kubota H, Taguchi K, Kobayashi D, Naruyama H, Hirose M, Fukuta K, Kubota Y, Yasui T, Yamada Y, Kohri K.
    Asian Pac J Cancer Prev; 2013 Nov 02; 14(12):7107-10. PubMed ID: 24460259
    [Abstract] [Full Text] [Related]

  • 16. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
    Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R, PROMID Study Group.
    J Clin Oncol; 2009 Oct 01; 27(28):4656-63. PubMed ID: 19704057
    [Abstract] [Full Text] [Related]

  • 17. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H, Inoue Y, Uchida K, Okugawa Y, Hiro J, Ojima E, Kobayashi M, Miki C, Kusunoki M.
    J Pediatr Surg; 2007 Jan 01; 42(1):259-60. PubMed ID: 17208578
    [Abstract] [Full Text] [Related]

  • 18. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H2-Blockers/Proton Pump Inhibitors and Corticosteroids With Octreotide.
    Minoura T, Takeuchi M, Morita T, Kawakami K.
    J Pain Symptom Manage; 2018 Feb 01; 55(2):413-419.e2. PubMed ID: 29122616
    [Abstract] [Full Text] [Related]

  • 19. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C, Zulian GB.
    Am J Hosp Palliat Care; 2009 Feb 01; 26(2):84-8. PubMed ID: 19088264
    [Abstract] [Full Text] [Related]

  • 20. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
    Berger J, Lester P, Rodrigues L.
    Am J Hosp Palliat Care; 2016 May 01; 33(4):407-10. PubMed ID: 25646530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.